BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Zephyr AI is a company that provides AI-powered solutions for various industries. The company is committed to protecting user privacy and has a comprehensive privacy policy in place.

Jeff Sherman

Zephyr AI

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Metric
Company Name	BridgeBio Pharma	Zephyr AI	4	BenevolentAI S.A.
Symbol			FDMT	BAI
MSH ID	COM:BRIDGEBIOPHARMA	BIO:ZEPHYRAI	COM:4DMOLECULARTHERAPEUTICS	COM:BENEVOLENT
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Technology	Biotechnology
Country	US	US	US
Stage	Post-IPO Equity
Employee Count		51	171
Website	bridgebiopharma.com	zephyrai.bio	4dmoleculartherapeutics.com
LinkedIn		zephyrai	4d-molecular-therapeutics-llc
Founders

Metric
Market Cap			1.20B
Enterprise Value
Monthly Web Traffic	23.81K	1.07K	10.96K	12.91K
Web Traffic Growth	0.19	-0.76	2.15	0.76
Valuation
Raised Capital	250M		300M

Metric
Revenue	20.72M	9.34M
Revenue (LTM)
Revenue (NTM)
Gross Profit	14.97M	9.34M
EBITDA	-107.12M	-89.02M
Operating Income	-112.87M	-98.85M
Net Income	-100.84M	-80.68M
EPS	-2.58
Diluted EPS	-2.58
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.64	1
Operating Profit Margin	-5.45	-10.58
EBITDA Margin	-5.17	-9.53
Net Profit Margin	-4.80	-8.64
Return on Equity	5.09	-0.51
Return on Assets	-0.17	-0.51
Return on Capital Employed	-0.20	-0.79

COM:BRIDGEBIOPHARMA

BridgeBio Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-14.82	-0.43
P/B Ratio	4.24	0.46
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	80.26	12.42
EV Multiple	-4.91	-0.82

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-141.50
Asset Turnover	0.06	0.06

Metric
Operating Cash Flow	-75.79M	-72.79M
Free Cash Flow	-78.56M	-74.20M
Cash Flow to Debt	-4.02	-10.46
Operating Cash Flow/Sales	-2.72	-7.28
Free Cash Flow Yield	-0.05	-1.03

Metric
Cash & Equivalents	249.11M	46.48M
Accounts Receivable
Inventory
Goodwill		29.92M
Debt to Capitalization	0.05	0.05
Debt to Assets	0.04	0.04
Current Ratio	18.07	5.93
Quick Ratio	32.65	3.65

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.82	3.20
R&D to Revenue	4.21	6.16
SG&A to Revenue	1.56	3.03